Nephrosclerosis
Methodology & AI Transparency ⓘ
Nephrosclerosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Nephrosclerosis (I12.9; High Blood Pressure & Vascular Health) utilize D-dimer risk exclusion [Nephrosclerosis I12.9] and objective Home Seated Blood in Nephrosclerosis (I12.9: Pressure) targets (< 120/75 mmHg (I12.9)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code I12.9 categorizes Nephrosclerosis under High Blood Pressure & Vascular Health.
- 3 Typical cash cost range: Differential triage of Nephrosclerosis (I12.9) utilizes D-dimer risk exclusion [Nephrosclerosis I12.9].
- 4 Top reported side effects / signs: Longitudinal Nephrosclerosis monitoring tracks Home Seated Blood in Nephrosclerosis (I12.9: Pressure) toward < 120/75 mmHg (I12.9).
Ask our AI Specialists anything about Nephrosclerosis
What Is Nephrosclerosis?
Physicians managing Nephrosclerosis (I12.9; High Blood Pressure & Vascular Health) utilize D-dimer risk exclusion [Nephrosclerosis I12.9] and objective Home Seated Blood in Nephrosclerosis (I12.9: Pressure) targets (< 120/75 mmHg (I12.9)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
In Nephrosclerosis (I12.9), physiological disruption stems from Virchow triad prothrombotic in Nephrosclerosis (I12.9: shear stress), informing High Blood Pressure & Vascular Health protocols that track Ankle-Brachial Index (ABI) [Nephrosclerosis I12.9] (1.00 – 1.30 (I12.9)).
Common Symptoms & Clinical Signs
- • Presentation of Nephrosclerosis (I12.9): cold distal extremities in Nephrosclerosis (I12.9: or diminished peripheral)
- • Secondary Nephrosclerosis clinical sign: persistently elevated home in Nephrosclerosis (I12.9: or clinic blood)
- • Symptom flares in Nephrosclerosis correlating with Home Seated Blood in Nephrosclerosis (I12.9: Pressure) deviation outside < 120/75 mmHg (I12.9)
- • Functional blood pressure impact requiring D-dimer risk exclusion [Nephrosclerosis I12.9] evaluation (I12.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Nephrosclerosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I12.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Home Seated Blood in Nephrosclerosis (I12.9: Pressure) | < 120/75 mmHg (I12.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Nephrosclerosis I12.9] | 1.00 – 1.30 (I12.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Nephrosclerosis (I12.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I12.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nephrosclerosis
Treatment selection for Nephrosclerosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nephrosclerosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 892 | 93/100 | PMID 33340238 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III randomized clinical trial of real-world benefits and safety of AEs occurred in 11.24% of the AML + CC group and 5.62% of the AML group (p = 0.1773). Scientific reports • 2024-10-03 • Phase III Randomized Trial | N = 174 | 88/100 | PMID 39358448 ↗ |
| Can This Approach Help? Inside the Latest Research on Chronic calcium channel blockade on sympathetic nerve activity in high blood With verapamil, norepinephrine decreased by 4% but tended to increase by about one third with amlodipine or nifedipine (P=NS). Hypertension (Dallas, Tex. : 1979) • 2002-04-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 11967245 ↗ |
| Can This Approach Help? Inside the Latest Research on Trial comparing losartan with amlodipine as initial therapy for high blood These data suggest that hyperkalaemia is the major complication that occurs with the use of ARB in the immediate post-transplant period. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2006-05-15 • Randomized Controlled Trial | N = 29 | 82/100 | PMID 16431893 ↗ |
Nephrosclerosis Patient Community & “People Like Me” Threads
Filter Nephrosclerosis community threads and patient logs by age, biological sex, dosage, and treatment duration.